Compare · MDT vs NRXS
MDT vs NRXS
Side-by-side comparison of Medtronic plc. (MDT) and Neuraxis Inc. (NRXS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDT and NRXS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $122.09B, about 1256.1x NRXS ($97.2M).
- Over the past year, MDT is down 1.2% and NRXS is up 103.7% - NRXS leads by 104.9 points.
- MDT has been more active in the news (29 items in the past 4 weeks vs 7 for NRXS).
- MDT has more recent analyst coverage (25 ratings vs 0 for NRXS).
- Company
- Medtronic plc.
- Neuraxis Inc.
- Price
- $94.77-0.74%
- $7.70-1.03%
- Market cap
- $122.09B
- $97.2M
- 1M return
- +2.12%
- +0.26%
- 1Y return
- -1.21%
- +103.70%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- AMEX
- IPO
- 2023
- News (4w)
- 29
- 7
- Recent ratings
- 25
- 0
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest MDT
- SEC Form 4 filed by Medtronic plc.
- SEC Form 4 filed by Medtronic plc.
- Medtronic Named to TIME Best Inventions of 2026 List for Stealth AXiS™ surgical system and Corsano™* multi-parameter wearable
- MiniMed Completes Separation from Medtronic
- Medtronic Completes Separation of MiniMed Group, Inc.
- SEC Form 144 filed by Medtronic plc.
- Amendment: SEC Form SC TO-I/A filed by Medtronic plc.
- SEC Form 425 filed by Medtronic plc.
- Medtronic Announces Final Results of MiniMed Group, Inc. Exchange Offer
- Amendment: SEC Form SC TO-I/A filed by Medtronic plc.
Latest NRXS
- NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives
- SEC Form 8-K filed by Neuraxis Inc.
- SEC Form 4 filed by Neuraxis Inc.
- SEC Form 4 filed by Neuraxis Inc.
- SEC Form 4 filed by Neuraxis Inc.
- SEC Form 3 filed by new insider Blanchard Craig Thomas
- NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
- NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives
- NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference
- iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026